Literature DB >> 14764102

Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.

John V Mitsios1, Afroditi P Tambaki, Morfis Abatzis, Nikolaos Biris, Maria Sakarellos-Daitsiotis, Constantinos Sakarellos, Ketty Soteriadou, John Goudevenos, Moses Elisaf, Demokritos Tsoukatos, Vassilios Tsikaris, Alexandros D Tselepis.   

Abstract

The platelet integrin receptor alphaIIbbeta3 plays a critical role in thrombosis and haemostasis by mediating interactions between platelets and several ligands but primarily fibrinogen. It has been shown previously that the YMESRADR KLAEVGRVYLFL (313-332) sequence of the alphaIIb subunit plays an important role in platelet activation, fibrinogen binding and alphaIIbbeta3-mediated outside-in signalling. Furthermore, we recently showed that the 20-residue peptide (20-mer) alphaIIb 313-332, is a potent inhibitor of platelet aggregation and fibrinogen binding to alphaIIbbeta3, interacting with fibrinogen rather than the receptor. In an effort to determine the sequence and the minimum length required for the biological activity of the above 20-mer, we synthesized seven octapeptides, each overlapping by six residues, covering the entire sequence and studied their effect on platelet activation as well as fibrinogen binding to activated platelets. We show for the first time that octapeptides containing the RAD sequence are capable of inhibiting platelet aggregation and secretion as well as fibrinogen binding to the activated alphaIIbbeta3, possibly interacting with the ligand rather than the receptor. This suggests that the RAD sequence, common to all the inhibitory peptides, is critical for their biological activity. However, the presence of the YMES sequence, adjacent to RAD, significantly increases the peptide's biological potency. The development of such inhibitors derived from the 313-332 region of the alphaIIb subunit may be advantageous against the RGD-like antagonists as they could inhibit platelet activation without interacting with alphaIIbbeta3, thus failing to further induce alphaIIbbeta3-mediated outside-in signalling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764102     DOI: 10.1111/j.1432-1033.2004.03990.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Exploration of the antiplatelet activity profile of betulinic acid on human platelets.

Authors:  Andreas G Tzakos; Vassiliki G Kontogianni; Maria Tsoumani; Eleni Kyriakou; John Hwa; Francisco A Rodrigues; Alexandros D Tselepis
Journal:  J Agric Food Chem       Date:  2012-07-03       Impact factor: 5.279

2.  Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization.

Authors:  Petros Tzimas; Maria Tsoumani; Dimitrios Giannakis; Kallirroi Kalantzi; Anastasios Petrou; Vasileios Chantzichristos; Nikolaos Sofikitis; Georgios Papadopoulos; Haralampos Milionis; Alexandros Tselepis
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

3.  Targeted molecular dynamics reveals overall common conformational changes upon hybrid domain swing-out in beta3 integrins.

Authors:  Davide Provasi; Marta Murcia; Barry S Coller; Marta Filizola
Journal:  Proteins       Date:  2009-11-01

4.  Role of platelet TLR4 expression in pathogensis of septic thrombocytopenia.

Authors:  Yong-Qiang Wang; Bing Wang; Yong Liang; Shu-Hua Cao; Li Liu; Xin-Nv Xu
Journal:  World J Emerg Med       Date:  2011

5.  Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib.

Authors:  Despoina Pantazi; Nikoleta Ntemou; Alexios Brentas; Dimitrios Alivertis; Konstantinos Skobridis; Alexandros D Tselepis
Journal:  Drug Des Devel Ther       Date:  2019-12-12       Impact factor: 4.162

6.  Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3.

Authors:  Wen Hwa Lee; Elisabeth Schaffner-Reckinger; Demokritos C Tsoukatos; Kelly Aylward; Vassilios Moussis; Vassilios Tsikaris; Paraskevi Trypou; Marion Egot; Dominique Baruch; Nelly Kieffer; Christilla Bachelot-Loza
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.